Zuellig Pharma Corporation launches One Family, One Heart, One Goal Initiative to promote Cardiovascular Health
Cardiovascular diseases are the leading cause of death globally. Locally, there are over 130,000 deaths related to Cardiovascular disease (CVD) noted in 2016.
Zuellig Pharma Corporation believes that physical fitness and good nutrition are pillars of good health that it kicked of its One Family, One Heart, One Goal Bloggers' Event earlier at the Crowne Plaza to spread CVD awareness.
Dr. Lourdes Ella Santos, Adult Cardiologist and Clinical Lipidologist talked more on the subject, focusing on Dyslipidemia (abnormal amount of cholesterol) in the blood.
Cardiovascular disease (CVD) encompasses a broad range of disorders which include diseases of the vasculature, the myocardium, the heart's electrical circuit, and congenital heart disease.
There are two types of cholesterol: LDL and HDL. Low-density lipoproteins (LDL) are sometimes called “bad” cholesterol. High levels of LDL cholesterol can build up in your arteries, causing heart disease. High-density lipoproteins (HDL) are referred to as “good” cholesterol.
When there is high level of bad cholesterol in your blood, it builds up in the walls of your arteries, arteries become narrow and the condition leads to atherosclerosis, a form of heart disease.
The dyslipidemia in metabolic syndrome is characterized by the presence of high plasma triglyceride and low HDL-cholesterol, which are associated with increase in small dense LDL and remnant lipoproteins, highly atherogenic lipoproteins.
There is a wide range of cholesterol-lowering arsenal available to patients ranging from statins to injectibles. Cholesterol medications help lower cholesterol, but effectiveness varies from person to person.
In 2O15, the U.S. Food and Drug Administration (FDA) approved the first-ever cholesterol-lowering injection treatments in the new class of PCSK9 inhibitors. PCSK9 is designed to be used in combination with statin therapy and dietary changes. Injectibles help decrease LDL. This treatment is tailored for lowering elevated LDL cholesterol and is often recommended for those who have genetic conditions that causes very high LDL levels and for whose cholesterol is difficult to control with other medications.
Zuellig Pharma Corporation is the authorized distributor of Amgen Philippines' PCSK9 in the country. Amgen Philippines Inc. and Zuellig Pharma Corporation are committed to improving the lives of patients with dyslipidemia by managing health risks associated with their condition.
Remember to make healthy lifestyle choices everyday. Medication can help control your cholesterol — but lifestyle changes matters, too.
Zuellig Pharma is one of the largest healthcare services groups in Asia and our purpose is to make healthcare more accessible. We provide world-class distribution, digital and commercial services to support the growing healthcare needs in this region.